Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q4 FY2020 Earnings Presentation
33 slides from Shilpa Medicare's earnings presentation, Jun 16, 2020
Slide 1: Shilpa Medicare Limited – Cover Letter to Exchange
? Shilpa Medicare Limited .... IInnovating for affordable healthcare Shilpa House# RAICHUR 12-6-214/A1 ,Hyderabad 584 135. Karnataka,lndia. - Road, Phone: +91-8532 - 238704, Fax: +91-8532-238876 CIN No. L85110KA1987PLC008739 E-mail: info@vbshilpa.com Website: www.vbshilpa.com Dated 16th June, 2020 T
Slide 2: Q4 & FY20 Results Presentation
Q4 & FY20 Results Presentation Shilpa Medicare Limited (SML) API Facility - Raichur
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ mat
Slide 4: Table of Contents
Table of Contents Company Overview 4 Financial Performance 17 Way Forward 26 Annexure 28 3
Slide 5: Company Overview
Company Overview Established presence in Active Specialized in Pharmaceutical Oncology and Non-Oncology Ingredients (APIs) Therapeutic and Formulations for domestic & areas, supported by strong R&D Robust research Affordable & international capability orientation resulting in Effective markets innov
Slide 6: Established Business Segments
Established Business Segments Description Capacities Manufacturing API products with highly précised API Isolator Technology 9 dedicated Blocks for Oncology & 4 Blocks for Non-Oncology The facility is approved by USFDA, WHO-GMP, Multi-product capability for Oncology & Non- EUGMP, TGA, PMDA,
Slide 7: Growth Business Segments
Growth Business Segments Description Capacities Company will pursue an aggressive IP strategy 2 Lines independent - single use lines (1000L Biologicals for Bio similar and NBE assets Bioreactor each) for production of MABS from mammalian cells 4 of the top 15 Biologic products in the pipeline
Slide 8: Growth Business Segments
Growth Business Segments Description Capacities Dermatological Company is engaged in R&D in various Dermatological products R&D is carried out at Shilpa Medicare’s Formulations 2 Products are ready to be filed under which 1 in-house R&D Facility Product is Niche Generic and 1 Product is Exhi
Slide 9: Strengths
R&D Competence Technology Edge SML’s Key Strengths Rich Scientific Talent Manufacturing Excellence 8
Slide 10: Research & Development Competence
Research & Development Competence API R&D Centre aids the development of Generics which meet international development standards R&D Formulation R&D centre develops Generic equivalents and super Generics for global markets of Injectable capabilities, a and Oral Formulations which are primarily used
Slide 11: Technology Edge API
Technology Edge API Improved safety in the process Reduced pain points in the process Reduced manual intervention which improves effluent quality Flexibility to use the equipment in multiple processes (with similar chemistries) The Company has made progress in the field of ‘Targeted Therap
Slide 12: Rich Scientific Talent API
Rich Scientific Talent API Devise new processes, or validate new processes, or refine existing ones, to optimize the manufacturing process 125+ Improve the yields by reducing costs, e.g. investigating alternative materials or new machinery to improve efficiency and quality in Scientists bottleneck a
Slide 13: Patents Status as on March 31, 2020
Patents Status as on March 31, 2020 Patents Filings Granted Pending - API 200 34 166 - Formulation 83 8 75 - Films Topical & Transdermal 46 2 44 - Biologicals 6 2 4 - Others 22 1 21 TOTAL 357 47 310 12
Slide 14: Product wise DMF filings as on March 31, 2020
Product wise DMF filings as on March 31, 2020 PMDA TGA & KFDA GCC WHO Name of the API US FDA EU/ EMEA TPD-Canada EDQM Japan Medsafe-NZ Korea & ROW Market Ambroxol HCl Azacitidine Bicalutamide Bendamustine HCl Bortezomib Busulfan Capecit
Slide 15: Product wise DMF filings as on March 31, 2020
Product wise DMF filings as on March 31, 2020 PMDA TGA & KFDA GCC WHO Name of the API US FDA EU/ EMEA TPD-Canada EDQM Japan Medsafe-NZ Korea & ROW Market Clofarabine Dimethyl Fumarate Axitinib Enzalutamide Pirfenidone Gemcitabine Hydrochloride (Process-2) Ibrutinib Teriflunom
Slide 16: Formulation Product Pipeline as on March 31, 2020
Formulation Product Pipeline as on March 31, 2020 Approved Patents Filings (Including Pending Tentative) US ANDA - On SML’s Name 22 13 9 - On Customer’s Name 20 12 8 TOTAL (In US) 42 25 17 - EU Filing 19 13 6 TOTAL (In US & EU) 61 38 23 15
Slide 17: Manufacturing Excellence
Manufacturing Excellence Facility Location Facility Type Dharwad R & D Biologicals Bengaluru R & D (All segments except Biologics) Raichur Unit I API (Onco – Non Oncology) Raichur Unit II API (Onco – Non Oncology) and R & D API India Jadcherla Unit Formulations (Onco & Adjuvant Therapy of Onco – Inj
Slide 18: Financial Performance
Filtration, Milling, Sieving & Packing Isolator Financial Performance 17
Slide 19: Covid19
Covid19 As per guidelines issued by the Government on March 24, 2020 the Company has been following all standard operating procedures at its Manufacturing, Research and Office sites The COVID-19 pandemic outbreak is impacting the global economy in multiple ways and also impacted on the pharmaceu
Slide 20: Abridged P&L Statement - Standalone
Abridged P&L Statement -Standalone (Rs.In Lakhs) Particulars Q4 Q4 Q-o-Q FY20 FY19 Y-o-Y FY20 FY19 Change Change (%) (%) Total Income (A+B+C+D+E) 20090 17450 15% 72755 64914 12% Total Revenue from 19793 17102 16% 71629 63361 13% Operations (A+B+C+D) •A PI (A ) 13304 10988 21% 50181 44212 14% •Formul
Slide 21: Abridged P&L Statement - Consolidated
(Rs. In Lakhs) Abridged P&L Statement - Consolidated Particulars Q-o-Q Y-o-Y Q4 Q4 FY20 FY19 Change FY20 FY19 Change (%) (%) Total Income (A+B+C) 22890 20261 13% 92485 74711 24% Revenue from operations (A) 20547 18134 13% 77204 70147 10% Service Income and License 1452 1817 -20% 13587 3192 326% fees
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet (Rs. In Lakhs) As at As at As at As at Assets 31.03.2020 31.03.2019 Equity & Liabilities 31.03.2020 31.03.2019 Audited Audited Audited Audited (1) NON- CURRENT ASSETS (1) EQUITY (a) Property , plant & equipment. 55,737.28 49,450.48 (a) Equity share capital 815.27 815.27 (b
Slide 23: Results Snapshot (Standalone)
Results Snapshot (Standalone) Division wise Revenue from Operations Key Highlights 13,304 (Rs. In Lakhs) 10,988 • Formulations' revenues were higher backed by the 4,812 launch of new products in the US 3,784 1,818 1,054 512 624 • API revenues were higher on account of delivering API Formulation Serv
Slide 24: Historical Revenue Statement – Standalone
Historical Revenue Statement – Standalone Total Revenue (ex-CRAMS): 13.66% CAGR since FY2018 (Rs. In Lakhs) 2018 2019 2020 2,332 1,553 2,334 2,553 1,126 3,117 3,027 8,968 3,602 8,909 38,821 16,596 34,817 19,115 36,511 Strong trends in underlying performance ex of CRAMS over the past few years 23
Slide 25: Corporate updates
Corporate updates Formulations USFDA held an audit from 13 February to 25 February at its finished Dosage Formulation Facility in Jadcherla, Form 483 issued with 15 observations, SML working with USFDA to Future Growth Businesses address the observations in a comprehensive manner The Biologicals
Slide 26: Managing Director’s Message
Managing Director’s Message Commenting on Q4 & FY’20 performance, Mr. Vishnukanth Chaturbhuj Bhutada, Managing Director Shilpa Medicare Limited said “We are pleased with the operating trends shown by the business during the year. Performance is tracking the expected milestones with 24% growth in ove
Slide 27: Way Forward
Low Volume Oncology Production Equipment Way Forward 26
Slide 28: Way Forward
Way Forward API Formulations Future Growth Businesses Plan to commercialize 3- To attain economies of Diversification into other therapeutic areas like 4 new molecules each scale by increasing Biologics, portfolio expansion to Transdermal Dosage year batch sizes Forms and Oral thin films formu
Slide 29: Annexures
Glass Lined Reactors in Intermediate Area Annexures 28
Slide 30: API Key Highlights
API Key Highlights : Increased the capacity of Tranexamic Acid by nearly about 100% from the pervious capacity & upgradation of existing API 29
Slide 31: Successful Regulatory Record
Successful Regulatory Record Segment Facility Audit Date and Agency Resolution API Unit-1 & Unit-2, Raichur USFDA inspection between Feb 3-7, 2020 EIR Received API Unit-1 & Unit-2, Raichur USFDA inspection between July 22-26, 2019 EIR Received API API Unit-1 GMP inspection by COFEPRIS-Mexico between
Slide 32: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Slide 33: Thank You
Temple – API Plant- Raichur Thank You 32